Joint RUSSCO-ASTRO-SPRO Session on Palliative Radiation Therapy in Incurable Patients: Keeping symptoms down and hope high-AM2019
Forty percent of radiation therapy in the United States is given with palliative intent. At the same time, palliative RT receives disproportionately low attention at national meetings, is not well studied on clinical protocols. Palliative RT remains more of an art than clinical science. Palliative RT practices around the world can shed light on how this situation can be rectified in the United States and more cost-effective, patient-centered palliative RT could be offered to patients with symptomatic disease progression. During the Annual Oncology Congress in November 2018 (in Moscow,Russia), RUSSCO-ASTRO held the first joint session, dedicated to palliative RT. Pragmatic solutions, logistical concerns, financial considerations, and ultimately – impact on patient’s well-being – were discussed from both US, Israel and Russian sides. There is no doubt that US radiation oncologists will become better equipped in providing cost-effective, patient-centered palliative RT after learning about international experience in this field.
This activity is available from February 7, 2020, through 11:59 p.m. Eastern time on February 6, 2023.
This activity was originally recorded at ASTRO’s 2019 Annual Meeting, September 15-18, 2019 in Chicago, IL.
The activity is designed to meet the interests of medical oncologists, radiation oncologists, radiation physicists, nurses, radiation therapists, radiation dosimetrists, residents, and specialists.
- Develop patient-centered, cost-effective palliative care clinic models.
- Apply the international experience in the field of palliative RT to the delivery of palliative care in US.
- Assess incurable and hospice patients for clinical benefit of palliative RT.
The following persons served as faculty for this activity:
Ben Corn, MD, FASTRO is employed at Shaare Zedek Medical Center and has nothing to disclose.
Natalia Dengina, MD, PhD is employed at Ulyanovsk Regional Clinical Oncology Center and has nothing to disclose.
Candice Johnstone, MD, MPH is employed at Medical College of WI and has nothing to disclose.
Timur Mitin, MD, PhD is employed at Oregon Health and Science University and receives compensation/remuneration/funding from Novocure, Inc.
Additionally, the Education and CME/MOC Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.